Solasia Pharma K.K. (TYO:4597)

Market Cap	8.74B +33.6%
Revenue (ttm)	429.00M +35.8%
Net Income	-876.00M
EPS	-3.69
Shares Out	273.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,027,000
Average Volume	69,072,830
Open	32.00
Previous Close	32.00
Day's Range	32.00 - 33.00
52-Week Range	27.00 - 48.00
Beta	1.21
RSI	43.27
Earnings Date	May 14, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 22
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4597

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.